Pulmonary embolism or acute deep vein thrombosis, in the first 1 weeks the patient can use of fibrinolytic agents including streptokinase an
Pulmonary embolism or acute deep vein thrombosis, in the first 1 weeks the patient can use of fibrinolytic agents including streptokinase and urokinase therapy. It is advocated that thrombolytic drugs can still be used within 2 weeks of thrombosis.
Streptokinase from hemolytic streptococcus broth produced by human urine extract, urokinase, both are effective activators, can activate the change in blood plasminogen to plasmin. This enzyme can hydrolyze fibrin into small molecule polypeptide, which can dissolve thrombus. Side effects: urokinase had no pyrogenic reaction, side effect than streptokinase for light. There may be bleeding such as wound bleeding but rarely occurs, fever, nausea and vomiting, headache, tiredness, chest tightness and rash. When complicated with severe bleeding, 10% of the 6- amino acid can be used for an acid of about 10 to 20ml, intravenous infusion, and infusion of fibrinogen when necessary.
In recent years, has been successfully developed only limited to the role of new thrombolytic drugs, thrombolytic drugs in the history of a new page. Human tissue type plasminogen activator (TPA), can specifically activate the surface of thrombus in the gel state of plasminogen, but the dissolved state in the circulating plasminogen had no effect, so there is no systemic effects, the disadvantage is the price expensive. Pro urokinase (Pro-UK), is the active role of urokinase, at home and abroad is still in the experimental stage.